Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY’s formulation on clinical performance NASHVILLE, Tenn. / Apr 12, 2024 / Business Wire / Revance Therapeutics, Inc. ( NASDAQ: RVNC), today announced two poster presentations on DAXXIFY® for the... Read More